Exo: expanding the universe of druggable enzymes

Exo debuted Wednesday with $25 million in series A funding to broaden the universe of druggable enzymes and improve drug selectivity by developing small molecules against non-catalytic, non-allosteric sites.

Exo Therapeutic Inc., which is backed by Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital, is built on research by co-founders Alan Saghatelian, a professor at the  Salk Institute for Biological Studies, CRISPR veteran David Liu from the Broad Institute of MIT and Harvard and Juan Pablo Maianti, who was a graduate student and postdoctoral researcher under Liu before he joined Exo as a scientist full-time...